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Abstract
Aim Clinicians mediate access to new technologies. Consequently, their views on specific devices may influence user
access to diabetes technology in mainstream care. As yet, little is known about clinicians’ views about closed-loop
systems. This qualitative study explored clinicians’ views on the likely impacts of future closed-loop systems in
mainstream diabetes care in England.
Methods We conducted interviews with 36 clinicians from a range of professional backgrounds in five hospital
outpatient clinics (two adult, two pregnancy, one paediatric) in England to explore possible consequences of closed-loop
systems for users and clinicians. Data analysis utilized a framework approach.
Results Clinicians reported a range of expected benefits for future users, including improved glucose control and
quality of life. Expected burdens included continued need for manual input and the risk of losing basic self-care
skills. In terms of future clinical workloads, three clinicians emphasized only positive impacts, seven emphasized
both positive and negative impacts, and 17 mentioned only negative impacts. Our most prominent finding, expressed
by 24 clinicians, was that closed-loop systems would generate initial challenges due to the need for staff training,
user education and support, and new analytical capacities, alongside existing intra-clinic variations in technological
experience.
Conclusions Clinicians recognize the value of closed-loop systems in terms of health benefits, but also identify a range
of concerns for both users and healthcare staff, which could impact negatively on user access. Future implementation
efforts should address these concerns by providing training and support for healthcare teams, taking varied technological
expertise into account.
Diabet. Med. 00, 1–7 (2020)
Introduction
In the absence of clinically available bioengineered solutions
such as encapsulated islet cells, the most promising thera-
peutic option for people with type 1 diabetes is the use of
closed-loop systems [1,2]. Closed-loop systems use algo-
rithms to process continuous glucose monitoring (CGM)
data and deliver precise and frequently updated doses of fast-
acting insulin to users via wearable insulin pumps. Studies of
closed-loop systems demonstrate significantly improved gly-
caemic control for a wide range of users, with associated
psychosocial benefits including perceived freedom from
diabetes, peace of mind and improved sleep [2–4]. From a
health systems perspective, widespread use of closed-loop
systems could reduce long-term complications and associ-
ated healthcare spending [5]. One US-focused analysis
suggested that closed-loop technology, although requiring
substantial initial investment, could lead to cumulative
Medicare savings of US $937 million after 25 years [6].
Alongside these promising findings, psychosocial research
has identified a number of user experience challenges that
could limit long-term usage in mainstream care, including
limited trust in automated insulin delivery, ‘deskilling’ (loss
of basic diabetes self-care capacities) and increased time
spent thinking about diabetes [2–4,7].
To date, less attention has been paid to clinicians’ views
on closed-loop systems, despite their crucial role in medi-
ating access to diabetes technology and related support [8].
In the vocabulary of candidacy theory, clinicians engage in
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negotiations with potential users, or ‘candidates’, in order to
adjudicate whether they meet relevant access criteria [9].
Yet different clinicians may interpret access criteria in
different ways, potentially leading to variable access to
treatment (as demonstrated previously in a wide range of
clinical settings) [10]. In particular, clinicians may hold
varied opinions regarding the clinical and psychosocial
benefit of new technologies and/or their likely impact on
service delivery [11]. These views could decrease their
willingness to issue positive adjudications when these are
otherwise warranted, due to fears regarding user burdens
and/or increased clinician workload. It is possible that
varied clinician attitudes towards technology may have
played a role in comparatively low and geographically
uneven levels of access to existing diabetes technologies such
as pumps and CGM in England, despite nationwide
guidelines issued by the National Institute for Health and
Care Excellence (NICE) [8,12].
NICE guidelines for future closed-loop systems have yet
to be formulated. Nevertheless, it is probable that future
access arrangements will continue to require clinician
adjudications regarding individual candidate users. Users’
access to future closed-loop systems may therefore be
influenced by varied clinician viewpoints relating to new
technology in general and/or closed-loop systems in
particular. Although some studies have explored clinician
views about current diabetes technologies such as pumps
and CGM [13–17], clinician perspectives on closed-loop
systems remain poorly understood. To explore clinician
views on closed-loop systems and their potential impacts
on future mainstream care for people with type 1 diabetes
in England, we aimed to investigate two key areas where
clinician attitudes might be especially relevant to future
adoption: (1) clinicians’ expectations regarding the likely
mix of benefits and burdens experienced by future users,




This was a qualitative study using semi-structured interviews.
We carried out 36 interviews with clinicians working at five
hospital diabetes outpatient clinics serving adult (two clin-
ics), pregnant (two clinics) and paediatric (one clinic)
populations with type 1 diabetes in three hospitals in
England, chosen to provide a range of geographical, socio-
economic and technology use contexts. Hospital 1 is a large
teaching hospital in an affluent area in the east of England,
with high levels of technology use; hospital 2 is a teaching
hospital in a less affluent area, also situated in the east of
England, with lower levels of technology use; and hospital 3
is a large teaching hospital in the north-west of England, also
in a less affluent area, and with low levels of technology use.
Participant recruitment
Following ethics approval from the Health Research Author-
ity (HRA; reference 18/HRA/115), we received permission
from local National Health Service (NHS) trusts to approach
members of outpatient clinic staff for interview. We aimed to
sample a range of professions in each clinic, including
dieticians, obstetricians, anaesthetists, midwives and psychol-
ogists, alongside nurses and physicians. We contacted poten-
tial participants via email, with a participant information
sheet and consent form, and offered all participants an
interview in person or by telephone at a convenient time, date
and place. In addition, we used a snowball sampling approach
to identify additional staff for interview, asking participants
for recommendations of other suitable candidates. We
attempted to interview clinicians from a range of professional
backgrounds (see Table 1 for participant characteristics) and
with varied familiarity with closed-loop technologies, ranging
from extensive personal involvement in trials (n = 10) to
clinicians with very limited knowledge (n = 6). The remain-
ing clinicians (n = 20) evidenced some familiarity with
closed-loop systems, often derived from media reports or
published papers. For participants who were unfamiliar with
closed-loop systems, CF gave brief descriptions of closed-loop
technology. Our study complied with European Medicines
Agency Guidelines for Good Clinical Practice.
Participants are identified using the following naming
convention: hospital number/clinic population/profession/
number of interviewee within clinic. Abbreviations for clinic
population and profession are given in parenthesis in relevant
headings of Table 1.
Data collection
CF conducted interviews in person (n = 29) and by telephone
(n = 7), between October 2017 and June 2018. All
What’s new?
• Clinician attitudes towards new technologies influence
outcomes in mainstream care. Little is known about
clinician views about the likely impacts of future closed-
loop systems in diabetes care.
• Alongside benefits and burdens for users, clinicians
expect closed-loop systems to generate health service
challenges due to heightened needs for training, user
support and analytical capacities.
• Clinicians identify a range of concerns for both users
and staff, which could impact negatively on user access.
Future implementation efforts should address these
concerns by providing training and support for health-
care teams.
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participants gave informed consent to participate and to
allow digital recording and transcription of interviews. We
used a semi-structured topic guide informed by relevant
literature and designed to allow for the exploration of a
range of issues, including clinician views about future closed-
loop usage, existing diabetes technologies and organizational
culture in outpatient clinics. Our topic guide focused on four
key topic areas: knowledge of closed-loop systems, user
experience of closed-loop technology, the likely impact of
closed-loop technologies on user access to technology, and
possible implications for future clinical workload (see Doc.
S1 for detailed topic guide). Interviews lasted between 28 and
73 min, with an average time of 47.5 min, a median time of
48 min and an interquartile range of 11 min.
Data analysis
We analysed the data using a combination of thematic and
framework analysis approaches, informedby theories of sense-
making, according to which attitudes towards technology are
influenced by preceding experiences, attitudes and values in
conjunction with the ‘affordances’, or capacities, of specific
devices or systems[18]. Initial coding of interview transcripts
took place alongside data collection to identify key themes and
generate a provisional coding structure. We then utilized this
provisional structure to undertake an initial thematic analysis,
using QSR NVivo software (see Table S1 for details of coding
structure). Our thematic analysis approach used a six-stage
approach: familiarization with the data, generating initial
codes, searching for themes, reviewing themes, defining and
naming themes, and producing an overall analysis [19].
We then supplemented our thematic analysis with frame-
work analysis, involving the use of a matrix with cells into
which summary qualitative data are entered by category
(rows) and cases (columns) [20]. This allowed us to identify
and explore patterns (categories) that cut across individual
clinician attitudes (cases). We focused in particular on two
key areas: clinician attitudes to envisaged benefits and
burdens for users using closed-loop technologies, and beliefs
regarding the impact of future closed-loop systems on clinical
workloads. We also used the matrix to record clinicians’
professional background, clinic location and antecedent
knowledge of closed-loop technologies and/or trials.
Results
Despite varied professional backgrounds (and varied levels of
involvement in mediating technology access), varied degree
of familiarity with closed-loop technology and varied clinic
characteristics (including location, population and levels of
technology use), our analysis found broad agreement
between clinicians across two key thematic areas relevant
to future closed-loop usage in England: (1) envisaged benefits
and burdens for users; and (2) the potential impact of closed-
loop technologies on future clinical workloads.
Users and closed-loop systems: expected benefits and
burdens
More than half of participants (n = 22) expected both
benefits and burdens to arise from future use of closed-loop
by users. Of the remaining interviewees, four clinicians
mentioned only burdens; one mentioned only benefits; and
six mentioned neither benefits nor burdens due to limited
knowledge of closed-loop systems. In the following sections,
envisaged benefits and burdens are separated for clarity,
although these were often mentioned side-by-side by inter-
viewees, reflecting the complex realities of clinical practice.
Envisaged benefits of closed-loop systems for users
A number of clinicians saw closed-loop systems as the next
step in insulin delivery technologies. One physician referred
to closed-loop as ‘the gold standard in terms of insulin
management’ (2/AD/Phys/1), whereas others described it as
‘revolutionary’ (1/PA/Diet/9) and ‘the way forward’ for
diabetes care (2/PR/Nurs/7). Several emphasized the
improved glycaemic control offered by closed-loop systems:
When you’re targeting that HbA1c . . . overnight blood
sugars make a big difference, post-meal blood sugars
make a big difference and . . . we know closed-loop can
really help to achieve that . . . [T]hat’s really challenging to






















Hospital 1 Pregnancy (PR) 1 2 2 2 1 – – 8
Paediatric (PA) 6 2 3 – – – 1 12
Hospital 2 Pregnancy (PR) 2 3 1 1 1 1 – 9
Adult (AD) 4 – – – – – – 4
Hospital 3 Adult (AD) 2 1 – – – – – 3
Total 15 8 6 3 2 1 1 36
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achieve on a pump or MDI [multiple daily injections]. (1/
PR/Diet/2)
In addition to highlighting improved control for users in
general, some interviewees anticipated particular benefit for
users with lower levels of engagement in self-care: ‘[It’s]
particularly good for patients who aren’t very motivated . . .
because the difficult stuff will be done for them’ (2/PR/Obs/
1). Some clinicians also emphasized potential improvements
in quality of life arising from the delegation of self-care to
closed-loop systems. Specific benefits in this context included
improved sleep, reduced diabetes burnout and a sense of
freedom from self-care burdens: ‘in the long run, [closed-loop
will] give [users] a bit of freedom, that they haven’t had for
all these years, where they’ve just been looking at diabetes
numbers’ (1/PA/Diet/10).
Envisaged burdens of closed-loop systems for users
Although most clinicians recognized at least some potential
benefits of closed-loop usage, they also highlighted many
potential burdens that users of closed-loop systems might
experience in mainstream care. Some related to technical and
logistical challenges such as the need for users to be
permanently attached to devices and to carry support
equipment with them. Other concerns centred on what were
perceived to be overly cautious (and non-user-modifiable)
control algorithms, and on the continued need for human
input. As one nurse stated, closed-loop systems are still
‘hybrid’ systems, meaning that users ‘still have to carb-count
and put those things in’ to activate manual prandial bolusing,
as well as undertaking frequent testing and calibrating (1/PA/
Nurs/7). One physician added that if future closed-loop
systems required only ‘minimum’ human input it would be
‘wonderful, but we’re not there yet’ (2/AD/Phys/2).
In addition to these technical burdens, clinicians raised two
broad areas of concern: the risk of deskilling and the
challenge of surrendering self-care control to algorithmic
closed-loop systems. With regard to deskilling, one physician
expressed their concern that closed-loop users might lose
familiarity with more basic self-care skills required for
multiple daily injections:
If something does go pear-shaped, they’ve got to make
decisions, they’ve got to revert perhaps to older technol-
ogy or to no technology . . . [Does] using closed-loop mean
that patients and families will deskill themselves . . . and if
things go wrong, they don’t know what to do[?] (1/PA/
Phys/8)
Another physician stated that closed-loop users ‘still need
to be able to know how to manage hypoglycaemia, they still
need to know how to manage ketones . . . because [closed-
loop] doesn’t answer all those problems’ (2/AD/Phys/3).
Challenges of surrendering control, secondly, arise
because closed-loop systems partially eliminate self-care
tasks of monitoring and responding to blood glucose levels.
Although this is, in part, an empowering feature of this
technology, it also requires people with diabetes to delegate
(frequently long-standing) self-care routines to an auto-
mated system. In this context, several interviewees cited
users’ long experience of self-care as a complicating factor
in closed-loop system adoption. One nurse described the
challenge as follows:
[P]eople are going to need a lot of reassurance . . . They’ve
got to step back, haven’t they, [from] all the work they’ve
been doing and the psychological control they’ve had,
because . . . you need to have a bit of OCD in order to go
on a pump and have good diabetes control. So then all of
a sudden they’re told to not do that anymore and leave it
to the closed loop system to do it. (3/AD/Nurs/2)
In this context, one physician suggested that clinicians tend
to underestimate the anxiety that new technologies such as
closed-loop systems can cause for users, which ‘can be very,
very disabling to diabetes [self-]care’ (3/AD/Phys/1). A
number of clinicians also highlighted the difficulty of
predicting users’ acceptance of, or resistance to, closed-loop
usage, describing this as ‘the great unknown’ (3/AD/Phys/3)
and as a potential barrier to closed-loop success.
Closed-loop technology and clinical workload
The prevailing view in the context of future clinical work-
loads was that closed-loop systems would generate addi-
tional short- to medium-term challenges due to the need for
staff training, user education and support, and new analytical
capacities. Of the 27 clinicians who expressed views regard-
ing future workload, three mentioned only positive impacts,
seven mentioned both positive and negative impacts, and 17
mentioned only negative impacts.
Positive envisaged impacts on clinical workload
Three clinicians suggested that closed-loop systems should
‘theoretically . . . free up time’ (1/PR/Obs/6) because algo-
rithmic insulin delivery would allow users to achieve
improved control with less need for intensive clinical input:
‘it will certainly reduce the workload of . . . medical teams in
terms of managing diabetes and the outcome will be
spectacularly better for patients’ (1/PR/Nurs/7). Others
raised the possibility that the improved glycaemic control
offered by closed-loop systems might help users to avoid
future complications, which in turn would reduce the clinical
effort needed to treat them. One midwife framed this
possibility in terms of healthcare spending, suggesting that
‘when you think of the complications, it would be a lot
cheaper to [use closed-loop systems than not]’ (2/PR/Midw/
7).
Several clinicians focused on the increased availability of
data arising from system readouts, which some saw as
reducing future workloads by limiting the need for face-to-
face contact. One physician suggested that this could reduce
4
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workload since users ‘can [upload] data . . . and they can send
it in’ (2/PR/Phys/2). Others pointed instead to the potential
for more efficient (rather than more remote) clinical work,
since more user data means
there will be . . . no second-guessing about what’s going
on . . . in-between [clinical encounters] . . . [W]e will have
a picture, if you like, of everything that’s going on. (2/PR/
Phys/8)
In the context of highly variable geographical availability
of diabetes outpatient clinics with the capacity to support
diabetes technology usage, one physician interpreted future
closed-loop systems as ‘democratizing’ access to diabetes
technology use by allowing a wider range of clinicians to
supervise the use of new systems: ‘[C]losed loop should make
pump therapy much, much more straightforward . . . and that
would take away, I think, some of the disparity in access to
skilled teams’ (2/PR/Phys/4). Others suggested that main-
stream closed-loop systems could reduce variations in terms
of care delivery within clinics, because the advanced capac-
ities offered by closed-loop technology may reduce the need
for advanced technological knowledge on the part of
different clinic personnel: ‘[S]ome of the variability would
be taken out of what we’re offering’ (1/PA/Diet/10).
Negative envisaged impacts on clinical workload
Although some clinicians identified potentially positive
impacts of closed-loop systems on future workload, most
were more negative. Participants highlighted three main
potential challenges: additional user training needs, time
pressure in consultations from increased data analysis
requirements, and risks of decreasing user engagement over
time.
First, several participants anticipated the need to provide
additional training and education to help users cope with the
logistical demands of using and maintaining hybrid closed-
loop systems, as well as the initial emotional challenge of
surrendering control to an algorithm. One physician stated,
for example, that new users ‘will need constant guidance . . .
on how to manage [closed-loop systems] on a day-to-day
basis’ (3/AD/Phys/1). Clinicians expected particularly high
demands for guidance at the start of closed-loop usage, and
for older users: ‘[I]n the initial stages . . . I think there will be
a lot of hand-holding. [T]he people who are bit older . . . will
probably be the ones who are ringing us constantly’ (3/AD/
Nurs/2).
Some concerns focused, secondly, on the additional data
analysis requirements arising from closed-loop system usage,
which were seen as challenging in terms of constrained
consultation timeframes:
I think what it would do is probably increase the amount
of time spent looking at glucose readings . . . [In t]he
current model in the clinic you . . . spend all of maybe 20
or 30 seconds looking at their blood glucose
concentrations . . . Now when you are then presented
with, potentially, pages and pages of output it may take a
lot longer to analyse that. (2/AD/Nurs/2)
Third, there were concerns that users of closed-loop
systems in home-living conditions may gradually exhibit
suboptimal behaviour and technology use, potentially lead-
ing to additional clinical work arising from poorer control.
In contrast to the initial hurdle of surrendering control over
self-care, they suggested that the challenge presented by
declining engagement was likely to increase over time. One
dietician invoked her experience of previous closed-loop
trials to describe how trial participants became ‘a bit more
lax . . . like they thought, oh, it’ll be alright because closed-
loop will pick it up’ (1/PA/Diet/10). In extremis, one
obstetrician expressed concern that some users might not
‘take any notice’ of their system ‘going completely wrong’ (1/
PR/Obs/6). Clinicians suggested that the same technological
capacity that allows a ‘broader range of people to [attain] an
acceptable level of control’ (2/PR/Phys/4) also risks encour-
aging the idea that closed-loop technology is ‘going to do
everything for [users, and] . . . fix everything’ (1/PR/Nurs/5).
In addition to highlighting specific challenges, clinicians
also identified hurdles in terms of meeting these challenges,
reflecting wider concerns regarding current pressures on
clinicians working with people with type 1 diabetes [11]. In
terms of providing additional training, for example, several
clinicians suggested that providing support for closed-loop
usage is ‘a big ask’, because many clinicians at present ‘don’t
[even] know anything about . . . pump[s]’ and since NHS
resources are ‘already so stressed’ (2/AD/Nurs/1). Counter-
balancing some participants’ optimism regarding the ‘de-
mocratization’ of care delivery within and across clinics, a
number of interviewees were troubled by the range of
preparedness and technological capacity evidenced by dif-
ferent clinics, with implications for their ability to meet
challenges posed by closed-loop adoption. One physician
stated that ‘some centres who are very well-funded will take
up technology quicker than others purely because they can
afford to hire . . . experienced staff . . . who have some
knowledge’ (3/AD/Phys/1). Referring to his own clinic, one
physician said: ‘I don’t think we are prepared enough . . .
[or] have enough resources to be able to provide it’ (2/AD/
Nurs/3).
Discussion
Participants in this study expected that the introduction of
closed-loop technology into mainstream care in England
would generate challenges as well as benefits for both users
and clinicians, with potential ramifications for clinician
adjudications regarding user candidacy for access to this
technology in future. Participants acknowledged the poten-
tial of closed-loop systems in terms of user well-being and
clinical effectiveness, but tended to emphasize pessimistic
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accounts of technology use in day-to-day self-care and
clinical oversight, especially (but not only) with regard to
the period immediately following technology adoption.
Participants offset envisaged benefits for people with type 1
diabetes (e.g. improved glycaemic control and quality of life)
by emphasizing potential burdens arising from the difficulty
of surrendering control, the continued need for human input,
and the risk of losing basic self-care capacities. Clinicians
similarly identified a range of potential benefits arising from
closed-loop usage, including lower levels of clinical input in
day-to-day diabetes care, fewer long-term complications for
people with diabetes, and more efficient care arising from
greater availability of glucose data. However, they also
highlighted a range of potential challenges, including the
need to provide additional technology-related training for
users, spend more time interpreting user data in consulta-
tions, and deal with complications arising from disengaged
users. They also emphasized the difficulty of meeting these
challenges in the wider NHS context, characterized by
underfunded and overstretched services and high variability
in inter- and intra-clinic technical capacity.
As described in candidacy theory approaches to health
service access, clinicians are required to mediate access to
services, including technology and associated support services,
by reaching adjudications regarding whether potential users –
‘candidates’ – meet relevant access criteria [9]. Our findings
suggest that clinicians’ adjudications regarding closed-loop
usage may be impacted by concerns regarding both user
burdens and implications of closed-loop technology for
clinical workload. If eligible users are prevented by clinicians
from gaining access to new technologies because of fears
regarding user experience and health service factors, the
undoubted benefits of closed-loop technologies may not be
fully realized at the population level. To forestall this eventu-
ality, clinicians involved in the use of closed-loop systems are
themselves likely to need significant additional support to
introduce and support the technology in routine care, not least
because psychosocial research suggests that some users could
rule themselves out of candidacy for long-term use [7].
Our participants did not always agree with each other.
Some clinicians suggested, for instance, that the automated
character of closed-loop technology could ‘democratize’
technology access by reducing variations in care provision,
whereas others argued that the mainstream adoption of
closed-loop could be challenged by inter-clinic variations in
technological expertise. As such, our study raises, but does
not settle, the question of whether future closed-loop systems
should be provided by a small number of specialist centres,
potentially improving care quality at the expense of user ease
of access, or by a larger number of geographically dispersed
outpatient clinics, which would increase ease of access but
risk introducing variations in the quality of care provision.
Our participants’ views also differed in some ways from
findings of previous user-focused studies, which emphasized
a mix of benefits and burdens for users of closed-loop
systems [2–4]. For example, although users in one study
believed their need for clinical support would decline
following an initial familiarization period [21], clinicians in
our study voiced concerns regarding the need for ongoing
and possibly increased support for users over time, as a result
of factors such as increased data analysis requirements and
declining user engagement.
Strengths of our study include in-depth interviews with
clinicians from different backgrounds serving a range of
populations, and with varied experience of closed-loop
technology. Our study is limited by uneven numbers of
interviewees serving pregnant (n = 17), paediatric (n = 12)
and adult (n = 7) populations, and by the dominance of
physicians (n = 15) as opposed to professions such as nursing
(n = 8) and dietetics (n = 6). Self-selection bias is possible
insofar as clinicians who agreed to participate may have been
positively disposed towards closed-loop technology and/or
participation in research projects. The geographical spread of
participants was limited by the low number of clinicians
recruited at hospital 3 (n = 3), and because a second clinic at
hospital 3, serving the paediatric population, declined to
participate. Although we aimed to recruit the widest possible
range of participants, it is possible that clinicians working in
other contexts may have different views regarding the
introduction of closed-loop technologies into mainstream
care. Future research could investigate the views of clinicians
working in a wider variety of geographical settings (including
settings beyond the UK), and serving a wider range of
populations, including minority ethnic populations whose
cultural beliefs may present challenges for closed-loop
adoption [15]. Future work could also explore the implica-
tions of users creating and using their own closed-loop
systems, bypassing health service access arrangements and
potentially requiring distinctive support arrangements [22].
In conclusion, our findings suggest that the introduction of
closed-loop systems to mainstream care in England may create
newchallenges aswell asbenefits, for bothusers andclinicians. In
order to minimize challenges and maximize benefits, implemen-
tation processes should take account of clinician concerns and
ensure the provision of adequate training and staffing resources.
Key user-focused training needs for clinicians involved in closed-
loop care will include technical support, data analytics and
aspects of user experience associated with use of automated
insulin therapy, ranging from the need to surrender control to the
need to maintain basic self-care capacities. Ideally, additional
resources should be targeted to reduce intra-clinic variation in
technological expertise, especially if closed-loop care is to be
provided in non-specialist clinics.
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